The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Hallmark symptoms of Cushing disease, including abdominal striae and facial rounding, were more common among younger patients than older patients.

North Carolina State University researchers continue to push the field of plant disease diagnosis forward, developing ...

Sinusitis can cause facial pressure, sinus headache, and other symptoms. Treatment may depend on the cause. A sinus infection, also known as sinusitis or rhinosinusitis, occurs when your nasal ...

A study led by Dr. Peter Canoll's lab, in collaboration with researchers at Columbia University Irving Medical Center, ...

COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. People with COPD often have trouble ...

Patients with skin of color are less likely to be diagnosed with a borderline reaction to patch testing than patients with lighter skin tones.

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...